Trial Profile
Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2016
Price :
$35
*
At a glance
- Drugs Romilkimab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Sanofi
- 22 Apr 2014 New trial record